Increased Circulatory Interleukin-17A Levels in Patients with Progressive and Leukotrichial Vitiligo
- PMID: 33968147
- PMCID: PMC8084637
- DOI: 10.1155/2021/5524566
Increased Circulatory Interleukin-17A Levels in Patients with Progressive and Leukotrichial Vitiligo
Abstract
Background: Vitiligo is a chronic condition characterized by skin depigmentation. Although not life-threatening, it significantly impacts quality of life. The pathophysiology of vitiligo remains poorly understood, and treatment options are limited. Mounting evidence supports the importance of autoreactive T cells and, particularly interleukin-17A- (IL-17A-) secreting Th17 cells, in vitiligo. IL-17A targeting has been proven successful in various inflammatory dermatological conditions, including psoriasis and lupus erythematosus.
Objective: We evaluated the relationship between serum levels of IL-17A and the clinicopathological characteristics of Vietnamese vitiligo patients.
Methods: In this cross-sectional study, we analyzed data from 52 nonsegmental vitiligo patients and 50 age- and sex-matched healthy individuals. Serum levels of IL-17A were measured using an enzyme-linked immunosorbent assay. We evaluated the correlation between IL-17A levels and clinical characteristics including leukotrichia, disease duration, vitiligo activity, and body surface area involvement.
Results: Patients with progressive vitiligo had significantly higher IL-17A levels than patients with stable vitiligo (P = 0.014) or healthy individuals (P = 0.002). In addition, serum IL-17A levels were higher in vitiligo patients with leukotrichia than in patients without it (P = 0.04). Furthermore, serum IL-17A levels were negatively correlated with age (r = -0.39, P = 0.004) and age of onset (r = -0.33, P = 0.016) in vitiligo patients.
Conclusions: Higher serum levels of IL-17A in patients with progressive vitiligo and leukotrichia suggest a potential role of IL-17A in melanocyte destruction in the epidermis and the follicular matrix.
Copyright © 2021 Thai Van Thanh Le et al.
Conflict of interest statement
The authors declare that there are no conflicts of interest.
Figures
Similar articles
-
Increased systemic and epidermal levels of IL-17A and IL-1β promotes progression of non-segmental vitiligo.Cytokine. 2017 Mar;91:153-161. doi: 10.1016/j.cyto.2016.12.014. Epub 2017 Jan 9. Cytokine. 2017. PMID: 28082234 Clinical Trial.
-
Dendritic cells sub-sets are associated with inflammatory cytokine production in progressive vitiligo disease.Arch Dermatol Res. 2021 Nov;313(9):759-767. doi: 10.1007/s00403-020-02168-w. Epub 2021 Jan 5. Arch Dermatol Res. 2021. PMID: 33403574
-
T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo.Clin Chim Acta. 2013 Sep 23;424:27-32. doi: 10.1016/j.cca.2013.05.005. Epub 2013 May 13. Clin Chim Acta. 2013. PMID: 23680073
-
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo.Cell Cycle. 2020 Feb;19(3):257-267. doi: 10.1080/15384101.2019.1707455. Epub 2020 Jan 5. Cell Cycle. 2020. PMID: 31905036 Free PMC article. Review.
-
The role of interleukins in vitiligo: a systematic review.J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2097-2111. doi: 10.1111/jdv.15016. Epub 2018 Aug 14. J Eur Acad Dermatol Venereol. 2018. PMID: 29704266
Cited by
-
Vitamin D and Interleukin-17: Are These Serum Biomarkers Useful in Non-Segmental Vitiligo? A Case Control Study from Central India.Indian J Dermatol. 2023 Nov-Dec;68(6):725. doi: 10.4103/ijd.ijd_442_23. Epub 2024 Jan 9. Indian J Dermatol. 2023. PMID: 38371538 Free PMC article.
-
Vitiligo: From mechanisms of disease to treatable pathways.Skin Health Dis. 2024 Sep 30;4(6):e460. doi: 10.1002/ski2.460. eCollection 2024 Dec. Skin Health Dis. 2024. PMID: 39624766 Free PMC article. Review.
-
Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art.Int J Mol Sci. 2023 Mar 3;24(5):4910. doi: 10.3390/ijms24054910. Int J Mol Sci. 2023. PMID: 36902341 Free PMC article. Review.
-
The role of aryl hydrocarbon receptor in vitiligo: a review.Front Immunol. 2024 Feb 1;15:1291556. doi: 10.3389/fimmu.2024.1291556. eCollection 2024. Front Immunol. 2024. PMID: 38361944 Free PMC article. Review.
-
Markers of Metabolic Abnormalities in Vitiligo Patients.Int J Mol Sci. 2024 Sep 23;25(18):10201. doi: 10.3390/ijms251810201. Int J Mol Sci. 2024. PMID: 39337683 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources